BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30

• Business

  The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium

  April 16, 2008

   · 

  1 min read
• Open Biosystems Launches Decode RNAi Viral Screening Pools for Low-Cost Genome-Scale RNAi Screens

  April 16, 2008

   · 

  3 min read
• Drug Development

  Takeda Pharmaceutical Co. Ltd. New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl)

  April 16, 2008

   · 

  4 min read
• Drug Development

  Ardea Biosciences, Inc. Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors

  April 16, 2008

   · 

  5 min read
• Drug Development

  Anthera Pharmaceuticals, Inc. Says DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

  April 16, 2008

   · 

  2 min read
• BioForest

  BioMS Medical to Present at EQUITIES Conference

  April 16, 2008

   · 

  2 min read
• Drug Development

  Novavax, Inc. Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate

  April 16, 2008

   · 

  4 min read
• Business

  Abbott Laboratories Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook

  April 16, 2008

   · 

  3 min read
• Drug Development

  UCB Group Data Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain

  April 16, 2008

   · 

  4 min read
• Drug Development

  Novartis Pharmaceuticals Corporation’s FTY720, a Novel Oral Therapy in Development for MS, Shows Sustained Benefits for the Majority of Patients After Three Years of Treatment

  April 16, 2008

   · 

  7 min read